remibrutinib
novartis
['remibrutinib']
plenary session : phase 2 trial of remibrutinib in sjogren's syndrome.
=&gt; improvement of the essdai
=&gt; improvement of salivary flux
=&gt; no effect on patient-reported outcomes (esspri)
#acr22
&gt;ms 
Annals of the Rheumatic Diseases (#1 research journal in Rheumatology) & RMD Open are the official @EULAR_ORG journals. High quality, peer reviewed research.